BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arafat AM, Kaczmarek P, Skrzypski M, Pruszyńska-Oszmałek E, Kołodziejski P, Adamidou A, Ruhla S, Szczepankiewicz D, Sassek M, Billert M, Wiedenmann B, Pfeiffer AF, Nowak KW, Strowski MZ. Glucagon regulates orexin A secretion in humans and rodents. Diabetologia 2014;57:2108-16. [PMID: 25063274 DOI: 10.1007/s00125-014-3335-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Park J, Shim H, Na A, Bae J, Im S, Song D. Orexin A regulates plasma insulin and leptin levels in a time-dependent manner following a glucose load in mice. Diabetologia 2015;58:1542-50. [DOI: 10.1007/s00125-015-3573-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
2 Scheen AJ, Paquot N. A new paradigm for treating obesity and diabetes mellitus. Nat Rev Endocrinol 2015;11:196-8. [DOI: 10.1038/nrendo.2015.3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
3 Farhy LS, Mccall AL. Glucagon – the new ‘insulin’ in the pathophysiology of diabetes: . Current Opinion in Clinical Nutrition and Metabolic Care 2015;18:407-14. [DOI: 10.1097/mco.0000000000000192] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
4 Lefèbvre PJ, Paquot N, Scheen AJ. Inhibiting or antagonizing glucagon: making progress in diabetes care. Diabetes Obes Metab 2015;17:720-5. [PMID: 25924114 DOI: 10.1111/dom.12480] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
5 Stožer A, Paradiž Leitgeb E, Pohorec V, Dolenšek J, Križančić Bombek L, Gosak M, Skelin Klemen M. The Role of cAMP in Beta Cell Stimulus-Secretion and Intercellular Coupling. Cells 2021;10:1658. [PMID: 34359828 DOI: 10.3390/cells10071658] [Reference Citation Analysis]
6 Skrzypski M, Billert M, Nowak KW, Strowski MZ. The role of orexin in controlling the activity of the adipo-pancreatic axis. J Endocrinol 2018;238:R95-R108. [PMID: 29848609 DOI: 10.1530/JOE-18-0122] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
7 Adeghate E, Lotfy M, D'Souza C, Alseiari SM, Alsaadi AA, Qahtan SA. Hypocretin/orexin modulates body weight and the metabolism of glucose and insulin. Diabetes Metab Res Rev 2020;36:e3229. [PMID: 31655012 DOI: 10.1002/dmrr.3229] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Sánchez-García A, Cabral-Pacheco GA, Zomosa-Signoret VC, Ortiz-López R, Camacho A, Tabera-Tarello PM, Garnica-López JA, Vidaltamayo R. Modular organization of a hypocretin gene minimal promoter. Mol Med Rep 2018;17:2263-70. [PMID: 29207107 DOI: 10.3892/mmr.2017.8142] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Rani M, Kumar R, Krishan P. Role of orexins in the central and peripheral regulation of glucose homeostasis: Evidences & mechanisms. Neuropeptides 2018;68:1-6. [DOI: 10.1016/j.npep.2018.02.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
10 Taleb N, Haidar A, Messier V, Gingras V, Legault L, Rabasa-Lhoret R. Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use. Diabetes Obes Metab 2017;19:13-23. [PMID: 27629286 DOI: 10.1111/dom.12789] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]